DK123484B - Analogifremgangsmåde til fremstilling af 1H-imidazo[4,5-β]pyrazin-2-oner. - Google Patents

Analogifremgangsmåde til fremstilling af 1H-imidazo[4,5-β]pyrazin-2-oner.

Info

Publication number
DK123484B
DK123484B DK379768AA DK379768A DK123484B DK 123484 B DK123484 B DK 123484B DK 379768A A DK379768A A DK 379768AA DK 379768 A DK379768 A DK 379768A DK 123484 B DK123484 B DK 123484B
Authority
DK
Denmark
Prior art keywords
pyrazin
imidazo
ones
preparation
analogous process
Prior art date
Application number
DK379768AA
Other languages
English (en)
Inventor
E Cragoe
J Jones
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of DK123484B publication Critical patent/DK123484B/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK379768AA 1967-08-08 1968-08-07 Analogifremgangsmåde til fremstilling af 1H-imidazo[4,5-β]pyrazin-2-oner. DK123484B (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65904267A 1967-08-08 1967-08-08
US72803368A 1968-05-09 1968-05-09

Publications (1)

Publication Number Publication Date
DK123484B true DK123484B (da) 1972-06-26

Family

ID=27097746

Family Applications (1)

Application Number Title Priority Date Filing Date
DK379768AA DK123484B (da) 1967-08-08 1968-08-07 Analogifremgangsmåde til fremstilling af 1H-imidazo[4,5-β]pyrazin-2-oner.

Country Status (11)

Country Link
US (1) US3507866A (da)
AT (1) AT291247B (da)
BE (1) BE719154A (da)
CH (1) CH516574A (da)
DE (1) DE1795062A1 (da)
DK (1) DK123484B (da)
ES (1) ES356976A1 (da)
FR (2) FR1578366A (da)
GB (1) GB1193035A (da)
IL (1) IL30463A0 (da)
NL (1) NL6810650A (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6903105B2 (en) * 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
US20050090505A1 (en) * 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
US20090253714A1 (en) * 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
US7745442B2 (en) * 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US7923041B2 (en) * 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US20070021439A1 (en) * 2005-07-25 2007-01-25 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
CN101522681B (zh) * 2006-08-02 2012-10-03 赛特凯恩蒂克公司 特定的化学个体、组合物和方法
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
ES2558517T3 (es) * 2006-08-02 2016-02-04 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y métodos que comprenden imidazopirimidinas
EP2078016B1 (en) 2006-10-19 2012-02-01 Signal Pharmaceuticals LLC Heteroaryl compounds, compositions thereof, and methods of treatment therewith
US7851484B2 (en) * 2007-03-30 2010-12-14 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
EP3091021B1 (en) 2009-10-26 2019-08-28 Signal Pharmaceuticals, LLC Methods of synthesis and purification of heteroaryl compounds
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
EA028060B1 (ru) 2011-07-13 2017-10-31 Сайтокинетикс, Инк. Комбинированная терапия бокового амиотрофического склероза
TWI629983B (zh) 2011-10-19 2018-07-21 標誌製藥公司 以ｔｏｒ激酶抑制劑治療癌症
PE20141696A1 (es) 2011-12-02 2014-11-08 Signal Pharm Llc Composiciones farmaceuticas de 7-(6-(2-hidroxipropan-2-il) piridin-3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino[2,3-b] pirazin-2(1h)-ona, una forma solida del mismo y metodos de su uso
AU2013202305B2 (en) 2012-02-24 2015-03-12 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP3150585A1 (en) 2012-12-17 2017-04-05 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
AU2013363215B2 (en) 2012-12-17 2018-03-01 Parion Sciences, Inc. 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
CN105188704B (zh) 2013-01-16 2017-09-19 西格诺药品有限公司 被取代的吡咯并嘧啶化合物、其组合物和使用其的治疗方法
KR102271344B1 (ko) 2013-04-17 2021-07-01 시그날 파마소티칼 엘엘씨 디하이드로피라지노-피라진을 사용한 암의 치료
WO2014172423A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
TWI654979B (zh) 2013-04-17 2019-04-01 美商標誌製藥公司 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
TWI656875B (zh) 2013-04-17 2019-04-21 美商標誌製藥公司 藉二氫吡并吡治療癌症
KR102221005B1 (ko) 2013-04-17 2021-02-26 시그날 파마소티칼 엘엘씨 전립선암 치료를 위한 디하이드로피라지노-피라진 화합물 및 안드로겐 수용체 길항제를 포함하는 조합 요법
TW201521725A (zh) 2013-04-17 2015-06-16 Signal Pharm Llc 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
US9782427B2 (en) 2013-04-17 2017-10-10 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
CN107474051B (zh) 2013-05-29 2020-10-30 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
WO2015160868A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
JP2017520603A (ja) 2014-07-14 2017-07-27 シグナル ファーマシューティカルズ，エルエルシー 置換ピロロピリミジン化合物を使用するがんの治療方法及びその組成物
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
SG11201912403SA (en) 2017-06-22 2020-01-30 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection

Also Published As

Publication number Publication date
AT291247B (de) 1971-07-12
FR1578366A (da) 1969-08-14
ES356976A1 (es) 1970-10-16
IL30463A0 (en) 1968-09-26
NL6810650A (da) 1969-02-11
DE1795062A1 (de) 1972-03-30
BE719154A (da) 1969-02-07
GB1193035A (en) 1970-05-28
FR8409M (da) 1971-03-31
CH516574A (de) 1971-12-15
US3507866A (en) 1970-04-21

Similar Documents

Publication Publication Date Title
DK123484B (da) Analogifremgangsmåde til fremstilling af 1H-imidazo[4,5-β]pyrazin-2-oner.
DK122885B (da) Analogifremgangsmåde til fremstilling af 1,4-dihydropyridinderivater.
DK121857B (da) Analogifremgangsmåde til fremstilling af 11β-alkyloxy-13β-alkylgona-1,3,5,(10)-trienderivater.
DK119878B (da) Analogifremgangsmåde til fremstilling af 2-methyl-3-carboxylsyreamido-quinoxalin-di-N-oxider-(1,4).
DK118820B (da) Analogifremgangsmåde til fremstilling af derivater af 5-nitro-2-furyl-isoxazoliner.
DK118877B (da) Analogifremgangsmåde til fremstilling af 3,1-benzoxazin-2-oner.
DK123868B (da) Analogifremgangsmåde til fremstilling af 3-hydroxycumarin-derivater.
DK129234B (da) Fremgangsmåde til fremstilling af levo-1-n-butyl-2',6'-pipecoloxylidid.
DK118288B (da) Analogifremgangsmåde til fremstilling af 2-halogenmethyl-3-carboxylsyreamido-quinoxalin-di-N-oxider-(1,4).
DK123232B (da) Analogifremgangsmåde til fremstilling af 3-alkoxy-17α-propinylestra-1,3,5(10)-trien-17β-oler.
DK118246B (da) Analogifremgangsmåde til fremstilling af 2-isothiuroniummethyl-3-carboxylsyreamido-quinozalin-di-N-oxid-(1,4)-halogenider.
DK125464C (da) Analogifremgangsmåde til fremstilling af 6-halogen-15β, 16β-methylen-pregnanderivater.
DK119166B (da) Fremgangsmåde til fremstilling af 1,4-bezodiazepinderivater.
DK128811B (da) Analogifremgangsmåde til fremstilling af 14α,17α-methylendioxypregnanderivater.
DK119559B (da) Analogifremgangsmåde til fremstilling af 4-pyrimidyl-1,4-dihydropyridinderivater.
DK121436B (da) Analogifremgangsmåde til fremstilling af 14α,17α-methylendioxypregnanderivater.
DK118291B (da) Analogifremgangsmåde til fremstilling af 10α-alkoxy-9,10-dihydroergolinderivater.
DK124882B (da) Analogifremgangsmåde til fremstilling af 17α-acyloxy-11β-methyl-19-norpregn-4-en-3,20-dioner.
DK126936B (da) Fremgangsmåde til fremstilling af 3-oxo-13β-alkylgona-4,9,11-triener.
DK121372B (da) Analogifremgangsmåde til fremstilling af 17β-(1-alkoxycycloalkyloxy)-2α,3α-epithio-5α-androstaner.
DK137494B (da) Fremgangsmåde til fremstilling af 1,4-benzodiazepinderivater.
DK120994B (da) Analogifremgangsmåde til fremstilling af N,N-dimethylaminoætyl-14β-hydroksy-5β-pregn-20-en-21-karboksylater.
DK121440B (da) Analogifremgangsmåde til fremstilling af 2,4-bis-morpholino- eller-thiomorpholino-5-carbalkoxy-pyrimidiner.
DK122175B (da) Analogifremgangsmåde til fremstilling af 3-oxo-13β-alkyl-17α-allyl-17β-hydroxygona-4,9,11-triener.
DK121235B (da) Fremgangsmåde til fremstilling af 1,4-benzodiazepinderivater.